deutetrabenazine

Ligand id: 8707

Name: deutetrabenazine

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 4
Topological polar surface area 38.77
Molecular weight 317.2
XLogP 2.69
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

Classification
Compound class Synthetic organic
Approved drug? Yes (FDA (2017))
IUPAC Name
(3R,11bR)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one
International Nonproprietary Names
INN number INN
10069 deutetrabenazine
Synonyms
Austedo® | SD-809 | SD809 | tetrabenazine D6
Database Links
CAS Registry No. 1392826-25-3 (source: WHO INN record)
GtoPdb PubChem SID 252827365
PubChem CID 73437646
Search Google for chemical match using the InChIKey MKJIEFSOBYUXJB-VFJJUKLQSA-N
Search Google for chemicals with the same backbone MKJIEFSOBYUXJB
Search PubMed clinical trials deutetrabenazine
Search PubMed titles deutetrabenazine
Search PubMed titles/abstracts deutetrabenazine
Search UniChem for chemical match using the InChIKey MKJIEFSOBYUXJB-VFJJUKLQSA-N
Search UniChem for chemicals with the same backbone MKJIEFSOBYUXJB
Comments
This is an orally available, deuterated analogue of tetrabenazine which can be administered in lower doses and in a simplified dosing regimen.

In drug discovery, replacing hydrogen atoms in drug compounds with deuterium (deuteration) is a technique employed to inhibit degradation of the drug and its active metabolites. The presence of the deuterium atoms attenuates CYP2D6-driven metabolic breakdown of the compound. This effects an increase in circulating half-lives and improves the duration of therapeutic effect and decreases the dose required to achieve therapeutic concentration [4].